UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 10-Q


[x]  Quarterly Report Pursuant to Section 13 or 15(d) of the Securities
     Exchange Act of 1934

     For the quarter ended September 30, 2002

                                       or

[ ]  Transition Report Pursuant to Section 13 or 15(d) of the Securities
     Exchange Act of 1934

     For the transition period from ___________ to _____________

     Commission File Number:   2-89332


                   INTERFERON SCIENCES RESEARCH PARTNERS, LTD.
             (Exact Name of Registrant as Specified in its Charter)


New Jersey                                       22-2502556
(State or other jurisdiction of                 (I.R.S. Employer
incorporation or organization)                   Identification No.)


783 Jersey Avenue, New Brunswick, New Jersey     08901
(Address of principal executive offices)        (Zip code)


(732) 249-3250
(Registrant's telephone number, including area code)



     Indicate  by check mark  whether the  registrant  (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during the  preceding  12 months  (or for such  shorter  period)  that the
registrant  was  required to file such  reports and (2) has been subject to such
filing requirements for the past 90 days.

                                  Yes X No ___



<PAGE>


                   INTERFERON SCIENCES RESEARCH PARTNERS, LTD.

                                TABLE OF CONTENTS




Part I.  Financial Information:

   Condensed Balance Sheets--September 30, 2002
     and December 31, 2001.....................................................1

   Condensed Statements of Operations--
     Three Months and Nine Months Ended September 30, 2002 and 2001............2

   Condensed Statements of Cash Flows -
     Nine Months Ended September 30, 2002 and 2001.............................3

   Notes to Condensed Financial Statements.....................................4

   Management's Discussion and Analysis of Financial
     Condition and Results of Operations.....................................5-6

Part II.  Other Information....................................................7

Signatures ....................................................................8



<PAGE>




                   INTERFERON SCIENCES RESEARCH PARTNERS, LTD.


                          PART I. FINANCIAL INFORMATION


KPMG LLP resigned as the  Partnership's  independent  accountants on November 6,
2002.  They were not engaged to and did not  perform a review of this  Quarterly
Report on Form 10-Q in accordance  with Statement on Auditing  Standards No. 71,
"Interim  Financial  Information",  although  such a review is required,  as the
General Partner lacks sufficient funds to pay for this review.


                            CONDENSED BALANCE SHEETS


                                                  September 30,   December 31,
                                                     2002             2001
                                                  (Unaudited)
                                                  ------------    ------------
ASSETS

Total assets                                       $ ---            $ ---
                                                  ============    ============
LIABILITIES AND PARTNERS' CAPITAL

Partners' capital
Limited partners                                   $ ---             $ ---
General partner                                      ---               ---
                                                  ------------    ------------

Total partners' capital                              ---               ---
                                                  ------------    ------------

Total liabilities and partners' capital            $ ---             $ ---
                                                  ============    ============











The accompanying notes are an integral part of these condensed financial
statements.


<PAGE>


                   INTERFERON SCIENCES RESEARCH PARTNERS, LTD.


                       CONDENSED STATEMENTS OF OPERATIONS
                                   (Unaudited)


                              Three Months Ended          Nine Months Ended
                                 September 30,              September 30,
                              -------------------         ----------------
                              2002          2001          2002        2001
                              ----          ----          ----        ----



Net income (loss)            $ ---         $ ---         $ ---       $ ---
                             =====         =====         =====       =====


Net income (loss) -
  Limited Partners           $ ---         $ ---         $ ---       $ ---

Net income (loss) -
  General Partner              ---           ---           ---         ---
                             -----         -----         -----       -----

Net income (loss)            $ ---         $ ---         $ ---       $ ---
                             =====         =====         =====       =====




                               Net income (loss)         Net income (loss)
                                   per unit                  per unit
                               -----------------         -----------------
Basic and diluted income
(loss) per unit - Limited
Partners (1038.7 units
outstanding)                 $ ---         $ ---         $ ---      $ ---
                             =====         =====         =====      =====





The accompanying notes are an integral part of these condensed financial
statements.


<PAGE>


                   INTERFERON SCIENCES RESEARCH PARTNERS, LTD.


                       CONDENSED STATEMENTS OF CASH FLOWS
                                   (Unaudited)



                                                        Nine Months Ended
                                                          September 30,
                                                       -------------------
                                                       2002           2001
                                                       ----           ----



Net change in cash                                    $  ---       $  ---
                                                      ---------    ----------

Cash at beginning of period                           $  ---       $  ---
                                                      ---------    ----------

Cash at end of period                                 $  ---       $  ---
                                                      ---------    ----------



















The accompanying notes are an integral part of these condensed financial
statements.


<PAGE>


                   INTERFERON SCIENCES RESEARCH PARTNERS, LTD.


                     NOTES TO CONDENSED FINANCIAL STATEMENTS
                                   (Unaudited)



Note 1.  Basis of Presentation

     The financial  information included herein is unaudited.  Such information,
however,  reflects  all  adjustments  (consisting  solely  of  normal  recurring
adjustments)  which are, in the opinion of the General  Partner  necessary for a
fair statement of the results for the interim  periods.  The results for interim
periods are not necessarily indicative of results to be expected for the year.

Note 2. Related Party Transactions

     During 1984, the  Partnership and Interferon  Sciences,  Inc. (ISI) entered
into several agreements including a Development  Contract whereby  substantially
all of the net proceeds of the 1984 sale of  Partnership  Units were paid to ISI
in periodic  payments over the term of the  Partnership's  development  program.
Such  payments were used to fund research and  development  and clinical  trials
necessary  for  obtaining   regulatory   approval  with  respect  to  a  topical
formulation  containing recombinant alpha interferon for the treatment of herpes
genitalis  (Alferon(R) Gel).  Through 1986, the Partnership paid ISI $4,555,000,
under this agreement.  Through 1990, the General  Partner,  Interferon  Sciences
Development Corporation (ISD), contributed $1,997,000, to the Partnership, which
used such funds to pay for additional  research and  development for the benefit
of the  Partnership.  Beginning in 1992,  ISI commenced  further  development of
Alferon Gel using ISI's natural source multi-species alpha interferon (Alferon N
Gel) in place of recombinant interferon.

Note 3.  Interferon Sciences Development Corporation and Interferon Sciences,
         Inc.

     ISD,  the  General  Partner,  is a wholly  owned  subsidiary  of ISI.  From
September 1986 through October 1990, ISD's total capitalization was used to fund
Partnership expenses.  ISD was totally dependent upon ISI for capital to be able
to fund the Partnership  during this period and is totally  dependent on ISI for
future  capital.  Beginning in 1992, ISI commenced  development of ALFERON N Gel
using its own funds.  ISI has had  continuing  losses  from  operations,  has an
accumulated  deficit,  a working  capital  deficiency,  and has  limited  liquid
resources which raise substantial doubt about its ability to continue as a going
concern and therefore there is substantial doubt about the Partnership's ability
to continue as a going concern.

     The Partnership is dependent on the General Partner for on-going  financial
support to cover incidental  costs of retaining the Partnership.  Such costs are
paid by ISI and, as they are de minimis,  are not reflected on the  accompanying
financial statements.


<PAGE>


                   INTERFERON SCIENCES RESEARCH PARTNERS, LTD.

                MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
                       CONDITION AND RESULTS OF OPERATIONS


Financial Condition and Liquidity

As of September  30, 1986,  the  Partnership  had exhausted all of its available
funds for the funding of research  and  development  of Alferon Gel. The General
Partner  agreed  to  contribute  up to an  additional  $433,000,  under  certain
conditions,  to continue  the  research.  Such amount was based on the number of
units sold in the offering. Notwithstanding that commitment, from September 1986
to October 1990, the General Partner contributed  $1,997,000 towards the cost of
such research. During May 1987, ISI filed a Product License Application with the
Food and Drug  Administration  (FDA) for approval to market  Alferon  Gel.  This
filing  was  supplemented  in  1989  with  an  updated  clinical  summary  and a
comprehensive  statistical  analysis of the completed  trials. At a meeting with
the FDA in February 1990, the FDA indicated that additional process  development
and clinical  trials  would be  necessary  prior to approval of Alferon Gel. ISI
believed,  at that  time,  that  the  costs to  complete  the  required  process
development  and  clinical  trials would be  substantial,  and there could be no
assurance that the clinical trials would be successful. As a result of the above
events,  in March 1992,  ISI withdrew its FDA Product  License  Application  for
Alferon Gel containing recombinant interferon.

     The General Partner does not anticipate  that the Partnership  will receive
any revenues in 2002. In addition, the Partnership is not in a position to incur
additional  expenses  since  it has  exhausted  all  its  available  funds.  The
independent  auditors'  report,  dated  February 20, 2002, on the  Partnership's
financial statements as of and for the year ended December 31, 2001 contained an
explanatory  paragraph  indicating that ISI has suffered  recurring  losses from
operations,  has an accumulated  deficit and has limited  liquid  resources that
raise substantial  doubt about the Partnership's  ability to continue as a going
concern.

     ISI does not  presently  intend to  exploit  ALFERON  Gel (the  Partnership
Product).  ISI had focused its clinical  efforts on ALFERON N Gel, a formulation
containing  ISI's  natural  alpha  interferon  (interferon  alfa-n3)  which  was
developed for the topical  treatment of viral diseases and cancers affecting the
skin  and  mucosal  tissues.  A Phase  2  pilot  clinical  trial  utilizing  its
reformulated  ALFERON N Gel has been  completed  for the  treatment  of cervical
dysplasia.  Under  the terms of the  Partnership  Agreement,  a  royalty  may be
payable to the Partnership by reason of the commercial exploitation of ALFERON N
Gel to the extent  that it utilizes  any of the  Partnership  Technology,  which
royalty will be adjusted based upon the  proportional  funding  contributions to
the  development of ALFERON N Gel by the Partnership and ISI. ISI currently does
not plan to continue the development of ALFERON N Gel.  However,  if ISI obtains
substantial additional financing in the future, or a sponsor can be secured, ISI
may exploit ALFERON N Gel for herpes  genitalis that may entitle the Partnership
to a royalty in respect to a product that competes with the Partnership Product.
This royalty will be adjusted based upon the proportional funding  contributions
to the development of ALFERON N Gel by the Partnership and ISI.

Results of Operations

     The Partnership was inactive during the nine months ended September 30,
2002 and 2001, and has generated no revenue nor incurred any expense during
these periods. The Partnership is dependent on the General Partner for on-going
financial support to cover incidental costs of retaining the Partnership.


<PAGE>


                   INTERFERON SCIENCES RESEARCH PARTNERS, LTD.



                           PART II. OTHER INFORMATION




Item 6.  Exhibits and Reports on Form 8-K

                  (b)   Reports on Form 8-K

                           There were no reports on Form 8-K filed during the
                           three months ended September 30, 2002.


<PAGE>


                   INTERFERON SCIENCES RESEARCH PARTNERS, LTD.


                               September 30, 2002





                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  in its  behalf by the
undersigned thereunto duly authorized.



                                Interferon Sciences Research Partners, Ltd.,
                                           A Limited Partnership
                                               (Registrant)

                                By:  Interferon Sciences Development
                                     Corporation - General Partner



DATE:  November 18, 2002        By:  /s/ Samuel H. Ronel, Ph.D.
                                     ---------------------------
                                         Samuel H. Ronel, Ph.D.
                                         President




DATE:  November 18, 2002        By:  /s/ Donald W. Anderson
                                     ---------------------------
                                         Donald W. Anderson
                                         Controller